Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
253 results:
1. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract] [Full Text] [Related]
2. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and pd-l1.
Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
[TBL] [Abstract] [Full Text] [Related]
3. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
[TBL] [Abstract] [Full Text] [Related]
4. Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic colorectal cancer.
Gherman A; Bolundut D; Ecea R; Balacescu L; Curcean S; Dina C; Balacescu O; Cainap C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541123
[TBL] [Abstract] [Full Text] [Related]
5. Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.
Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
[TBL] [Abstract] [Full Text] [Related]
6. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
[TBL] [Abstract] [Full Text] [Related]
7. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
8. A comprehensive multi-omics analysis identifies a robust scoring system for cancer-associated fibroblasts and intervention targets in colorectal cancer.
Wang F; Li Z; Xu T; Zhang Q; Ma T; Li S; Wang X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):124. PubMed ID: 38478111
[TBL] [Abstract] [Full Text] [Related]
9. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer.
Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
[TBL] [Abstract] [Full Text] [Related]
10. TMEM160 promotes tumor immune evasion and radiotherapy resistance via pd-l1 binding in colorectal cancer.
Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
[TBL] [Abstract] [Full Text] [Related]
11. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Pennel KAF; Hatthakarnkul P; Wood CS; Lian GY; Al-Badran SSF; Quinn JA; Legrini A; Inthagard J; Alexander PG; van Wyk H; Kurniawan A; Hashmi U; Gillespie MA; Mills M; Ammar A; Hay J; Andersen D; Nixon C; Rebus S; Chang DK; Kelly C; Harkin A; Graham J; Church D; Tomlinson I; Saunders M; Iveson T; Lannagan TRM; Jackstadt R; Maka N; Horgan PG; Roxburgh CSD; Sansom OJ; McMillan DC; Steele CW; Jamieson NB; Park JH; Roseweir AK; Edwards J
J Exp Clin Cancer Res; 2024 Mar; 43(1):64. PubMed ID: 38424636
[TBL] [Abstract] [Full Text] [Related]
12. colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and pd-l1 expression.
Ho YH; Hsu CY; Yau Li AF; Liang WY
Hum Pathol; 2024 Mar; 145():80-85. PubMed ID: 38423221
[TBL] [Abstract] [Full Text] [Related]
13. Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.
He R; Huang S; Lu J; Su L; Gao X; Chi H
Front Immunol; 2024; 15():1362709. PubMed ID: 38415252
[TBL] [Abstract] [Full Text] [Related]
14. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and sipd-l1 for synergistic targeted cancer treatment.
Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
[TBL] [Abstract] [Full Text] [Related]
15. Progress of PD-1/pd-l1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract] [Full Text] [Related]
16. Programmed Cell Death Ligand 1 Expression in CD163 + Tumor-associated Macrophages in cancer Gland Rupture Microenvironment.
Baş Y; Yilmaz B; Acar SF; Karadağ İ
Appl Immunohistochem Mol Morphol; 2024 Apr; 32(4):176-182. PubMed ID: 38314768
[TBL] [Abstract] [Full Text] [Related]
17. Potential prognosis and immunotherapy predictor TFAP2A in pan-cancer.
Niu C; Wen H; Wang S; Shu G; Wang M; Yi H; Guo K; Pan Q; Yin G
Aging (Albany NY); 2024 Jan; 16(2):1021-1048. PubMed ID: 38265973
[TBL] [Abstract] [Full Text] [Related]
18. Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target.
Huang X; Zhang W; Yang N; Zhang Y; Qin T; Ruan H; Zhang Y; Tian C; Mo X; Tang W; Liu J; Zhang B
Mol Cancer; 2024 Jan; 23(1):19. PubMed ID: 38243263
[TBL] [Abstract] [Full Text] [Related]
19. Targeting the NAT10/NPM1 axis abrogates pd-l1 expression and improves the response to immune checkpoint blockade therapy.
Qin G; Bai F; Hu H; Zhang J; Zhan W; Wu Z; Li J; Fu Y; Deng Y
Mol Med; 2024 Jan; 30(1):13. PubMed ID: 38243170
[TBL] [Abstract] [Full Text] [Related]
20. Role of stromal pd-l1 expression in colorectal liver metastasis.
Takasu C; Morine Y; Yoshikawa K; Nakao T; Tokunaga T; Nishi M; Kashihara H; Wada Y; Yoshimoto T; Shimada M
BMC Cancer; 2024 Jan; 24(1):97. PubMed ID: 38233811
[TBL] [Abstract] [Full Text] [Related]
[Next]
